Esperion Therapeutics
3.87
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Esperion Therapeutics
Esperion Therapeutics, Inc., una compañía farmacéutica, desarrolla y comercializa medicamentos para el tratamiento de pacientes con colesterol elevado de lipoproteínas de baja densidad. Sus principales productos candidatos son las tabletas NEXLETOL (ácido bempedoico) y NEXLIZET (ácido bempedoico y ezetimiba) para el tratamiento de pacientes con enfermedad cardiovascular aterosclerótica o hipercolesterolemia familiar heterocigota. La empresa tiene un acuerdo de licencia y colaboración con Daiichi Sankyo Europe GmbH; y Serometrix para obtener la licencia de su programa inhibidor oral de PCSK9 de molécula pequeña. Esperion Therapeutics, Inc. se incorporó en 2008 y tiene su sede en Ann Arbor, Michigan.
Trade GPT
Similar Stocks
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.